Campylobacter jejuni is a predominant cause of human gastroenteritis worldwide. Source-attribution studies indicate that chickens are the main reservoir for infection, thus elimination of C. jejuni from poultry would significantly reduce the burden of human disease. We constructed glycoconjugate vaccines combining the conserved C. jejuni N-glycan with a protein carrier, GlycoTag, or fused to the Escherichia coli lipopolysaccharide-core. Vaccination of chickens with the protein-based or E. coli-displayed glycoconjugate showed up to 10-log reduction in C. jejuni colonization and induced N-glycan-specific IgY responses. Moreover, the live E. coli vaccine was cleared prior to C. jejuni challenge and no selection for resistant campylobacter variants was observed. Analyses of the chicken gut communities revealed that the live vaccine did not alter the composition or complexity of the microbiome, thus representing an effective and low-cost strategy to reduce C. jejuni in chickens and its subsequent entry into the food chain.
glycoconjugate vaccines, Campylobacter jejuni, lipopolysaccharide core, genomics, chicken, Glycomics
NCBI PubMed ID: 27221144Publication DOI: 10.1038/srep26511Journal NLM ID: 101563288Publisher: London: Nature Publishing Group
Correspondence: nothaft@ualberta.ca; cszymans@ualberta.ca
Institutions: Department of Biological Sciences, University of Alberta, Edmonton, AB, Canada, Alberta Glycomics Centre, University of Alberta, Edmonton, AB, Canada, Delta Genomics, Edmonton, AB, Canada, Department of Agricultural, Food &Nutritional Science, University of Alberta, Edmonton, AB, Canada, Human Health Therapeutics, National Research Council, Ottawa, Canada
Methods: 13C NMR, 1H NMR, DNA techniques, ELISA, Western blotting, biological assays, genetic methods, bioinformatic analysis, conjugation, chicken vaccination
Found